Abstract
HIV infection remains a major world health problem more than 20 years after discovery of the virus. Mental disorders make individuals more vulnerable to behaviors that transmit HIV and interfere with HIV treatment adherence. The evidence supporting the need for optimal provision of mental health care in HIV clinics is mounting, along with evidence that these disorders can be treated successfully. Disorders of mental life include brain diseases (eg, depression, bipolar disorder, schizophrenia, and dementia), personality disorders, addictions, and psychologic disruptions, which contribute to the spread of the virus through their influence on behavior. However, although evidence exists that successful treatment of co-occurring mental disorders leads to improved HIV outcomes, integrated mental health care in HIV clinics remains grossly suboptimal.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Kubler-Ross E: On Death and Dying. New York: Macmillan; 1969.
McHugh PR, Slavney PR: The Perspectives of Psychiatry, edn 2. Baltimore: The Johns Hopkins University Press; 1998.
Angelino AF, Treisman GJ: Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001, 33:847–856.
Atkinson JH, Heaton RK, Patterson TL, et al.; HNRC Group: Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord 2008, 108:225–234.
Cysique LA, Deutsch R, Atkinson JH, et al.; HNRC Group: Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007, 13:1–11.
Gibbie T, Hay M, Hutchison CW, Mijch A: Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sex Health 2007, 4:227–232.
Rabkin JG, McElhiney MC, Ferrando SJ: Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS 2004, 18(Suppl 1):S43–S48.
Narrow WE, Rae DS, Robins LN, Regier DA: Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys’ estimates. Arch Gen Psychiatry 2002, 59:115–123.
Asch SM, Kilbourne AM, Gifford AL, et al.; HCSUS Consortium: Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med 2003, 18:450–460.
Himelhoch S, Medoff DR: Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS 2005, 19:813–822.
Himelhoch S, Medoff DR, Oyeniyi G: Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS 2007, 21:732–739.
Waldrop-Valverde D, Valverde E: Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS 2005, 19:326–334.
Sledjeski EM, Delahanty DL, Bogart LM: Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS 2005, 19:728–736.
Alciati A, Gallo L, Monforte AD, et al.: Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol 2007, 22:33–40.
Cruess DG, Douglas SD, Petitto JM, et al.: Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry 2005, 162:2125–2130.
Pieper AA, Treisman, GJ: Drug treatment of depression in HIV-positive patients: safety considerations. Drug Safety 2005, 28:753–762.
Thompson A, Silverman B, Dzeng K, Treisman GJ: Psychotropic medications and HIV. Clin Infect Dis 2006, 42:1305–1310.
Nakimuli-Mpungu E, Musisi S, Mpungu SK, Katabira E: Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatry 2006, 163:1349–1354.
Maxwell S, Scheftner WA, Kessler HA, Busch K: Manic syndrome associated with zidovudine treatment. JAMA 1988, 259:3406–3407.
Brouilette MJ, Routy JP: Abacavir sulfate and mania in HIV. Am J Psychiatry 2007, 164:979–980.
Shah MD, Balderson K: A manic episode associated with efavirenz therapy for HIV infection. AIDS 2003, 17:1713–1714.
Weisler RH, Keck PE Jr, Swann AC, et al.; SPD417 Study Group: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005, 66:323–330.
Sajatovic M, Ramsay E, Nanry K, Thompson T: Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. Int J Geriatr Psychiatry 2007, 22:945–950.
Ferrando SJ, Nims C: HIV-associated mania treated with electroconvulsive therapy and highly-active antiretroviral therapy. Psychosomatics 2006, 47:170–174.
Regier DA, Farmer ME, Rae DS, et al.: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990, 264:2511–2518.
Himelhoch S, McCarthy JF, Ganoczy D, et al.: Understanding associations between serious mental illness and HIV among patients in the VA Health System. Psychiatr Serv 2007, 58:1165–1172.
Cournos F, Guido JR, Coomaraswamy S, et al.: Sexual activity and risk of HIV infection among patients with schizophrenia. Am J Psychiatry 1994, 151:228–232.
Koen L, Uys S, Niehaus DJ, Emsley RA: Negative symptoms and HIV/AIDS risk-behavior knowledge in schizophrenia. Psychosomatics 2007, 48:128–134.
Bagchi A, Sambamoorthi U, McSpiritt E, et al.: Use of antipsychotic medications among HIV-infected individuals with schizophrenia. Schizophr Res 2004, 71:435–444.
Ziedonis DM, Smelson D, Rosenthal RN, et al.: Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005, 11:315–339.
Aylward EH, Brettschneider PD, McArthur JC, et al.: Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry 1995, 152:987–994.
Anthony IC, Ramage SN, Carnie FW, et al.: Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005, 64:529–536.
Hauser KF, El-Hage N, Stiene-Martin A, et al.: HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 2007, 100:567–586.
Shiramizu B, Gartner S, Williams A, et al.: Circulating proviral HIV DNA and HIV-associated dementia. AIDS 2005, 19:45–52.
Glass JD, Fedor H, Wesselingh SL, McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995, 38:755–762.
Bhaskaran K, Mussini C, Antinori A, et al.; CASCADE Collaboration: Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008, 63:213–221.
Mahajan SD, Aalinkeel R, Sykes DE, et al.: Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 2008, 1203:133–148.
Dhillon NK, Peng F, Bokhari S, et al.: Cocaine-mediated alteration in tight junction protein expression and modulation of CCL2/CCR2 axis across the blood-brain barrier: implications for HIV-dementia. J Neuroimmune Pharmacol 2008, 3:52–56.
Letendre SL, Marquie-Beck J, Ellis RJ, et al.; CHARTER Group: The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007, 2:120–127.
Letendre S, Marquie-Beck J, Capparelli E, et al.; CHARTER Group: Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65:65–70.
Muñz-Moreno JA, Rodríguez C, Prats A, et al.: Recommended earlier initiation of ART based on nadir CD4 cell count as a risk factor for HIV-related neurocognitive impairment. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.
Uldall KK, Harris VL, Lalonde B: Outcomes associated with delirium in acutely hospitalized acquired immune deficiency syndrome patients. Compr Psychiatry 2000, 41:88–91.
Angelino AF, Treisman GJ: Issues in co-morbid severe mental illnesses in HIV infected individuals. Int Rev Psychiatry 2008, 20:95–101.
Meagher DJ, Moran M, Raju B, et al.: Phenomenology of delirium. Assessment of 100 adult cases using standardized measures. Br J Psychiatry 2007, 190:135–141.
Cohen BJ: Theory and Practice of Psychiatry. New York: Oxford University Press; 2003.
Eysenck HJ: Genetic and environmental contributions to individual differences: the three major dimensions of personality. J Personality 1990, 58:245–261.
Costa PT Jr, Widiger TA, eds: Personality Disorders and the Five-Factor Model of Personality. Washington, DC: American Psychological Association; 1994.
Moore DJ, Atkinson JH, Akiskal H, et al.; HNRC Group: Temperament and risky behaviors: a pathway to HIV? J Affect Disord 2005, 85:191–200.
Meade CS, Graff FS, Griffin ML, Weiss RD: HIV risk behavior among patients with co-occurring bipolar and substance use disorders: associations with mania and drug abuse. Drug Alcohol Depend 2008, 92:296–300.
Chander G, Himelhoch S, Moore RD: Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 2006, 66:769–789.
Palepu A, Tyndall M, Yip B, et al.: Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003, 32:522–526.
Lucas GM, Gebo KA, Chaisson RE, et al.: Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1treatment outcomes in an urban clinic. AIDS 2002, 16:767–774.
Tucker JS, Burnam MA, Sherbourne CD, et al.: Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003, 114:573–580.
de Jong BC, Prentiss D, McFarland W, et al.: Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr 2005, 38:43–46.
Miguez MJ, Shor-Posner G, Morales G, et al.: HIV treatment in drug abusers: impact of alcohol use. Addict Biol 2003, 8:33–37.
Wood E, Kerr T, Tyndall MW, Montaner JS: A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008, 22:1247–1256.
Wood E, Hogg RS, Yip B, et al.: Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005, 19:1189–1195.
Desai MM, Rosenheck RA, Desai RA: Prevalence and correlates of human immunodeficiency virus testing and posttest counseling among outpatients with serious mental illness. J Nerv Ment Dis 2007, 195:776–780.
Dilley JW, Woods WJ, Loeb L, et al.: Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. Acquir Immune Defic Syndr 2007, 44:569–577.
Williams ML, Bowen AM, Timpson SC, et al.: HIV prevention and street-based male sex workers: an evaluation of brief interventions. AIDS Educ Prev 2006, 18:204–215.
Himelhoch S, Medoff DR, Oyeniyi G: Efficacy of group psychotherapy to reduce depressive symptoms among HIVinfected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS 2007, 21:732–739.
Berger S, Schad T, von Wyl V, et al.: Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS 2008, 22:767–775.
Antoni MH, Carrico AW, Durán RE, et al.: Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosom Med 2006, 68:143–151.
Plotzker RE, Metzger DS, Holmes WC: Childhood sexual and physical abuse histories, PTSD, depression, and HIV risk outcomes in women injection drug users: a potential mediating pathway. Am J Addict 2007, 16:431–438.
Gwandure C: Sexual assault in childhood: risk HIV and AIDS behaviours in adulthood. AIDS Care 2007, 19:1313–1315.
Boarts JM, Sledjeski EM, Bogart LM, Delahanty DL: The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS Behav 2006, 10:253–261.
Vranceanu AM, Safren SA, Lu M, et al.: The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS 2008, 22:313–321.
Radcliffe J, Fleisher CL, Hawkins LA, et al.: Posttraumatic stress and trauma history in adolescents and young adults with HIV. AIDS Patient Care STDS 2007, 21:501–508.
Willenbring ML: Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS 2005, 19(Suppl 3):S227–S237.
Himelhock S, Moore RD, Treisman GJ, Gebo KA: Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr 2004, 37:1457–1463.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vlassova, N., Angelino, A.F. & Treisman, G.J. Update on mental health issues in patients with HIV infection. Curr Infect Dis Rep 11, 163–169 (2009). https://doi.org/10.1007/s11908-009-0024-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11908-009-0024-4